Simcere Pharmaceutical Group (SCR) Tops Q4 EPS by 2c

Simcere Pharmaceutical Group (NYSE: SCR) reported Q4 EPS of $0.12, $0.02 better than the analyst estimate of $0.10. Revenue for the quarter came in at $81.2 million versus the consensus estimate of $86.35 million.

For earnings history and earnings-related data on Simcere Pharmaceutical Group (SCR) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• Northrim BanCorp (NRIM) Tops Q1 EPS by 54c
• First Bancshares (FBMS) Tops Q1 EPS by 6c